Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCN 2023 | Emerging therapies in MOGAD

Jodie M. Burton, MD, MSc, FRCPC, University of Calgary, Alberta, Canada, discusses emerging therapies for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Currently, due to the relative novelty of MOGAD as a demyelinating disease, treatment strategies are repurposed from NMOSD, a better-understood condition. While this approach may be effective in the acute phase of both diseases, there is a need for more specialized therapies in managing and preventing MOGAD relapses. Intravenous immunoglobulin has demonstrated efficacy in preventing ongoing disease activity and relapses, but its cost and availability pose challenges. Mycophenolate mofetil, an oral immunosuppressant commonly used for autoimmune diseases, has shown effectiveness in MOGAD. Other promising immunosuppressants include tocilizumab and satralizumab, both IL-6 inhibitors, and azathioprine, which is notable for its affordability and widespread availability. Additionally, rozanolixizumab, an FDA-approved anti-FcRn monoclonal antibody for myasthenia gravis, is under investigation for its potential application in MOGAD. This interview took place at the World Congress of Neurology (WCN) 2023 in Montreal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Jodie Burton reports the following disclosures: honoraria, educational support/activities/ad boards for Roche, consultation with Alexion, Horizon.